Genmab's petosemtamab combination therapy shows strong efficacy in Phase 2 trials for head and neck cancer, achieving a 28.2-month median overall survival rate.
Genmab reported positive Phase 2 data for petosemtamab in combination with pembrolizumab for first-line HNSCC, showing a median overall survival of 28.2 months and a 63% ORR. These results significantly outperform historical benchmarks for recurrent/metastatic HNSCC, which typically see survival in the 10-12 month range, validating the company's bispecific antibody strategy. The data provides a strong foundation for the ongoing Phase 3 LiGeR clinical program.
It is a bispecific antibody targeting EGFR and LGR5, designed to inhibit EGFR signaling, trigger EGFR degradation in cancer stem-like cells, and enhance innate immune-mediated activity.
It is significantly higher than the typical 10-12 month median overall survival observed in recurrent/metastatic HNSCC patients.
Genmab A/S announced positive Phase 2 results for its investigational antibody petosemtamab in combination with pembrolizumab for first-line head and neck squamous cell carcinoma. The treatment demonstrated a median overall survival of 28.2 months and an overall response rate of 63%, significantly outperforming historical benchmarks for the disease.
The results are significant because the 28.2-month median overall survival is substantially higher than the typical 10-12 month survival rate for recurrent or metastatic HNSCC.